The first patient has been enrolled in a Phase 1 trial by the NHLBI that's evaluating fostamatinib as a treatment for sickle cell disease.

IPA: Inhibition of platelet aggregation; iv.: Intravenous. The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or ...

These tests detect platelet aggregation induced by agonists as changes in electrical resistance between ... and treatment may be required prior to platelet function testing. Regarding controlled ...

Factor VIII gene was introduced into hematopoietic stem cells in men with hemophilia. The annualized bleeding rate went from 10 to 0. No worrisome gene integrations were seen. The content of this ...

First patient enrolled in NIH/NHLBI-sponsored Phase 1 Study of fostamatinib, Rigel's oral SYK inhibitor "Our Phase 1 study evaluating fostamatinib in patients with sickle cell disease is an ...

We developed a phage-assisted continuous evolution platform for rapid selection of protein aggregation inhibitors from genetically encoded cyclic peptide libraries in Escherichia coli. This ...

and pointed out that abnormal adhesion of neutrophils to the vascular wall and subsequent formation of microthrombi by platelet aggregation may inhibit pulmonary blood flow and exacerbate COVID-19 ...

Human platelet lysates (HPL) are abundant in bioactive factors, and numerous studies have demonstrated their beneficial effects on neurological diseases, including their anti-neuroinflammatory ability ...

Data related to interventions focused explicitly on low-dose platelet aggregation inhibitors. Two reviewers conducted all data extraction procedures, which were reviewed and confirmed by another ...

Nevertheless, on the basis of these early reports, over-the-counter availability of PPIs, their widespread use in patients on DAPT and the potential for harm, many national and international ...

Jiangsu Key Laboratory of Drug Design and Optimization and State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, China Jiangsu Key Laboratory of Drug Design and ...